MSD stops trials of BTK inhibitor for blood cancers

News
MSD stops trials of BTK inhibitor for blood cancers

MSD has called a halt to three trials of BTK inhibitor nemtabrutinib – added to its pipeline through its $2.7 billion acquisition of ArQule – after initial results suggested that the drug's benefits are unlikely to outweigh its risks.

In a statement, MSD – known as Merck & Co in the US and Canada – said that it is discontinuing the clinical development programme for nemtabrutinib (MK-1026), a non-covalent BTK inhibitor that was being tested for leukaemia and other haematological malignancies.

The decision affects the phase 3 BELLWAVE programme and was prompted by data from  BELLWAVE-011, which was comparing MSD's drug to Pfizer's Imbruvica (ibrutinib) and AstraZeneca's Calquence (acalabrutinib) – both covalent BTK inhibitors – as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

After a review confirmed a safety signal in the trial, MSD decided to also discontinue two other phase 3 trials – BELLWAVE-008 and BELLWAVE-010 – which were testing the drug, respectively, as a monotherapy in patients with previously untreated CLL/SLL without TP53 aberrations and as a combination regimen in relapsed/refractory CLL/SLL.

"Following careful analyses of the data from BELLWAVE-011, the decision has been made to discontinue development of nemtabrutinib across the entire clinical programme," said Dr Marjorie Green, head of global oncology clinical development at Merck Research Laboratories. "We continue to pursue solutions for patients with haematologic malignancies."

It's a disappointing end for a drug candidate that had been held up by MSD as a future blockbuster when it bought ArQule in 2019, offering activity against both wild-type BTK and mutant forms of the enzyme that are associated with resistance to other BTK inhibitors.

Since then, prospects for the programme have diminished, with MSD taking multiple charges in its accounting as a result of developmental delays and increased competition in the BTK inhibitor category, particularly from other non-covalent entrants like Eli Lilly's Jaypirca (pirtobrutinib).

Jaypirca was the first non-covalent or reversible BTK inhibitor to be approved by the FDA, and has grown rapidly since its first launch in 2023, with sales growing 63% to $585 million in the first nine months of 2026.

Jaypirca's label was extended last month to include first-line treatment of CLL/SLL, but the drug still lags behind BeOne Medicine's masrket-leading covalent inhibitor Brukinsa (zanubrutinib), as well as Calquence and Imbruvica, as it tends to be saved for use when resistance to BTK drugs has developed.